Complimentary access to the JTO and a 25% discount on the publication fees for the newest open-access IASLC journal, JTO CRR. Both JTO and JTO CRR feature novel research about the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO is now among the top 5% of all oncology journals and the leading journal that is entirely focused on thoracic oncology.
JTO and JTO CRR feature novel research about the prevention, detection, diagnosis, and treatment of all thoracic malignancies. With an Impact Factor of 13.357, JTO is now among the top 5% of all oncology journals and the leading journal that is entirely focused on thoracic oncology. It emphasizes a multidisciplinary approach and includes original research, reviews and opinion pieces. JTO CRR, IASLC’s open access companion title, publishes a range of manuscripts from subset analyses of published trials to high-quality case reports.
JTO by the Numbers
11
out of 244 in 2019 Oncology Journals
3
out of 64 in 2019 Respiratory Journals
13.357
Impact Factor (up from 12.460 in 2018)
1,704%
increase in 6 years full-text article downloads
Recent journal articles
Postoperative radiotherapy for completely resected Masaoka/Masaoka-Koga stage II/III thymoma improves overall survival: An updated meta-analysis of 4,746 patients
First-Line Nivolumab Plus Ipilimumab vs Chemotherapy in Advanced Non-Small Cell Lung Cancer With Tumor PD-L1 ≥ 1%: Patient-Reported Outcomes From CheckMate 227 Part 1
The Survival Advantage of Lobectomy over Wedge Resection Lessens, as Health-Related Life Expectancy Decreases
The feasibility and safety of routine thoracic surgeries in the low risk areas during the COVID-19 pandemic
Salvage immunotherapy with pembrolizumab in patients hospitalized for life-threatening complications of non-small-cell lung cancer.
Lazarus Response to Tepotinib for Leptomeningeal Metastases in a MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma Patient: Case Report
Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC – an update from the PACIFIC trial
Coronavirus Infectious Disease Epidemic (COVID-19): where we are, what can be done and hope for.
Discover the JTO
JTO.org offers numerous ways to stay abreast of novel research and information vital to your daily oncology practice. Join the JTO reader community to:
More than 80 international experts compose the JTO Editorial Board, allowing for a quick turn-around time of 5.4 days to initial decision, and an average of 7 days for revisions, a fast track category, publish on acceptance (within 5 days), and promotion of select articles via social media and press releases.
JTO emphasizes a multidisciplinary approach and includes original research (clinical trials and translational or basic research), reviews, and opinion pieces. Authors can take advantage of Elsevier's Researcher Academy, Navigate your research journey with Researcher Academy—free e-learning modules on navigating your career developed by global experts.
JTO reviewers are given the privilege of getting the first look at novel research, phase III data, and potentially practice-changing concepts. Email your CV to [email protected].
New JTO Collections
Discover the JTO CRR
Providing a more clinical focus, the JTO CRR contains phase I thoracic oncology clinical trials and single-arm phase II trials, as well as case reports, subset analyses of a published trials, database analyses, retrospective trials, and large single-institution series.
In addition to the content discussed previously, JTO CRR also accepts region-specific clinical trials, subspecialty thoracic oncology studies, and select high-quality meeting reports.
To become a JTO CRR Reviewer email your CV to [email protected].
